Literature DB >> 2926498

O6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts.

S C Schold1, T P Brent, E von Hofe, H S Friedman, S Mitra, D D Bigner, J A Swenberg, P Kleihues.   

Abstract

The level of O6-alkylguanine-deoxyribonucleic acid (DNA) alkyltransferase (AT) was determined in 15 human brain-tumor xenografts in athymic mice. This enzyme is a primary intracellular repair mechanism for lesions produced at the O6 position of guanine by a wide range of alkylating agents, including nitrosoureas and procarbazine. Its activity ranged from undetectable in five tumor lines to 2338 fmol/mg protein in N-1941, a human glioblastoma xenograft. The sensitivity of 10 of these xenografts to procarbazine was determined and it was found that four of the five tumor lines with AT levels of more than 100 fmol/mg protein had growth delays after procarbazine treatment of less than 20 days, whereas all five lines with undetectable AT levels had growth delays of over 30 days. The primary cytotoxic DNA adduct produced by procarbazine (namely, O6-methylguanine) was found to be significantly higher in two sensitive lines with low AT levels than in a highly resistant line with a high AT level. These data suggest that the AT levels of individual brain tumors can be used as predictive indicators of their susceptibility to drugs that exert their antineoplastic effect primarily by O6-alkylation of guanine in nuclear DNA.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2926498     DOI: 10.3171/jns.1989.70.4.0573

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  30 in total

1.  4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine.

Authors:  Rui Zhu; Mao-Chin Liu; Mei-Zhen Luo; Philip G Penketh; Raymond P Baumann; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  J Med Chem       Date:  2011-10-17       Impact factor: 7.446

Review 2.  Malignant glioma: neuropathology and neurobiology.

Authors:  Matthias Preusser; Christine Haberler; Johannes A Hainfellner
Journal:  Wien Med Wochenschr       Date:  2006-06

3.  A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001.

Authors:  Deborah T Blumenthal; Cathryn Rankin; Keith J Stelzer; Alexander M Spence; Andrew E Sloan; Dennis F Moore; Gilbert D A Padula; Susan B Schulman; Mark L Wade; Elisabeth J Rushing
Journal:  Int J Clin Oncol       Date:  2014-11-19       Impact factor: 3.402

4.  Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine.

Authors:  K Tano; S Shiota; J Collier; R S Foote; S Mitra
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

5.  Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.

Authors:  Antonio Silvani; Elena Lamperti; Paola Gaviani; Marica Eoli; Anna Fiumani; Andrea Salmaggi; Chiara Falcone; Graziella Filippini; Andrea Botturi; Amerigo Boiardi
Journal:  J Neurooncol       Date:  2007-06-19       Impact factor: 4.130

6.  Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.

Authors:  H S Friedman; P J Houghton; S C Schold; S Keir; D D Bigner
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.

Authors:  Jennifer A Quinn; Sara Xiaoyin Jiang; James Carter; David A Reardon; Annick Desjardins; James J Vredenburgh; Jeremy N Rich; Sridharan Gururangan; Allan H Friedman; Darell D Bigner; John H Sampson; Roger E McLendon; James E Herndon; Stevie Threatt; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

8.  BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.

Authors:  Thomas Reithmeier; Erika Graf; Tobias Piroth; Michael Trippel; Marcus O Pinsker; Guido Nikkhah
Journal:  BMC Cancer       Date:  2010-02-02       Impact factor: 4.430

9.  Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival.

Authors:  C G Robinson; J M Palomo; G Rahmathulla; M McGraw; J Donze; L Liu; M A Vogelbaum
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

10.  Comparison between BCNU and procarbazine chemotherapy for treatment of gliomas.

Authors:  H B Newton; J Bromberg; L Junck; M A Page; H S Greenberg
Journal:  J Neurooncol       Date:  1993-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.